Catalyst Capital Advisors LLC Sells 23,848 Shares of Cencora, Inc. (NYSE:COR)

Catalyst Capital Advisors LLC lowered its stake in shares of Cencora, Inc. (NYSE:COR) by 83.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,563 shares of the company’s stock after selling 23,848 shares during the period. Catalyst Capital Advisors LLC’s holdings in Cencora were worth $1,025,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Sylvest Advisors LLC acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $1,105,000. Insight Wealth Strategies LLC lifted its holdings in Cencora by 124.6% during the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock valued at $4,549,000 after purchasing an additional 11,232 shares during the last quarter. Cerity Partners LLC boosted its position in Cencora by 10.1% during the third quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock worth $8,881,000 after purchasing an additional 3,610 shares during the period. Thurston Springer Miller Herd & Titak Inc. increased its holdings in shares of Cencora by 71.1% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock valued at $1,583,000 after purchasing an additional 2,928 shares during the last quarter. Finally, Portfolio Design Labs LLC bought a new position in shares of Cencora in the third quarter valued at about $1,404,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

COR has been the topic of a number of research reports. Mizuho started coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target on the stock. Robert W. Baird boosted their price objective on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Evercore ISI increased their target price on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. UBS Group boosted their price target on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company increased their price objective on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $277.90.

Cencora Price Performance

Shares of NYSE COR opened at $243.03 on Tuesday. The stock has a market capitalization of $46.97 billion, a PE ratio of 34.57, a P/E/G ratio of 1.49 and a beta of 0.49. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.53. The business has a fifty day moving average price of $238.75 and a two-hundred day moving average price of $237.41.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities analysts predict that Cencora, Inc. will post 15.36 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. Cencora’s dividend payout ratio is 31.29%.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.